Literature DB >> 27343716

Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation.

Karen Ballen1, Kwang Woo Ahn2, Min Chen3, Hisham Abdel-Azim4, Ibrahim Ahmed5, Mahmoud Aljurf6, Joseph Antin7, Ami S Bhatt8, Michael Boeckh9, George Chen10, Christopher Dandoy11, Biju George12, Mary J Laughlin13, Hillard M Lazarus14, Margaret L MacMillan15, David A Margolis16, David I Marks17, Maxim Norkin18, Joseph Rosenthal19, Ayman Saad20, Bipin Savani21, Harry C Schouten22, Jan Storek23, Paul Szabolcs24, Celalettin Ustun25, Michael R Verneris15, Edmund K Waller26, Daniel J Weisdorf25, Kirsten M Williams27, John R Wingard18, Baldeep Wirk28, Tom Wolfs29, Jo-Anne H Young15, Jeffrey Auletta30, Krishna V Komanduri31, Caroline Lindemans32, Marcie L Riches33.   

Abstract

Alternative graft sources (umbilical cord blood [UCB], matched unrelated donors [MUD], or mismatched unrelated donors [MMUD]) enable patients without a matched sibling donor to receive potentially curative hematopoietic cell transplantation (HCT). Retrospective studies demonstrate comparable outcomes among different graft sources. However, the risk and types of infections have not been compared among graft sources. Such information may influence the choice of a particular graft source. We compared the incidence of bacterial, viral, and fungal infections in 1781 adults with acute leukemia who received alternative donor HCT (UCB, n= 568; MUD, n = 930; MMUD, n = 283) between 2008 and 2011. The incidences of bacterial infection at 1 year were 72%, 59%, and 65% (P < .0001) for UCB, MUD, and MMUD, respectively. Incidences of viral infection at 1 year were 68%, 45%, and 53% (P < .0001) for UCB, MUD, and MMUD, respectively. In multivariable analysis, bacterial, fungal, and viral infections were more common after either UCB or MMUD than after MUD (P < .0001). Bacterial and viral but not fungal infections were more common after UCB than MMUD (P = .0009 and <.0001, respectively). The presence of viral infection was not associated with an increased mortality. Overall survival (OS) was comparable among UCB and MMUD patients with Karnofsky performance status (KPS) ≥ 90% but was inferior for UCB for patients with KPS < 90%. Bacterial and fungal infections were associated with poorer OS. Future strategies focusing on infection prevention and treatment are indicated to improve HCT outcomes.
Copyright © 2016 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Infection; Leukemia; Umbilical cord blood

Mesh:

Year:  2016        PMID: 27343716      PMCID: PMC5008458          DOI: 10.1016/j.bbmt.2016.06.012

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  40 in total

1.  Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor grafts.

Authors:  Yi-Bin Chen; Julie Aldridge; Haesook T Kim; Karen K Ballen; Corey Cutler; Grace Kao; Deborah Liney; Greg Bourdeau; Edwin P Alyea; Philippe Armand; John Koreth; Jerome Ritz; Thomas R Spitzer; Robert J Soiffer; Joseph H Antin; Vincent T Ho
Journal:  Biol Blood Marrow Transplant       Date:  2011-10-19       Impact factor: 5.742

2.  Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study.

Authors:  Yuqian Sun; Fanyi Meng; Mingzhe Han; Xi Zhang; Li Yu; He Huang; Depei Wu; Hanyun Ren; Chun Wang; Zhixiang Shen; Yu Ji; Xiaojun Huang
Journal:  Biol Blood Marrow Transplant       Date:  2015-03-31       Impact factor: 5.742

Review 3.  Mismatched related and unrelated donors for allogeneic hematopoietic cell transplantation for adults with hematologic malignancies.

Authors:  Mary Eapen; Paul O'Donnell; Claudio G Brunstein; Juan Wu; Kate Barowski; Adam Mendizabal; Ephraim J Fuchs
Journal:  Biol Blood Marrow Transplant       Date:  2014-05-23       Impact factor: 5.742

4.  Unrelated umbilical cord blood transplant for adult acute lymphoblastic leukemia in first and second complete remission: a comparison with allografts from adult unrelated donors.

Authors:  David I Marks; Kwang Ahn Woo; Xiaobo Zhong; Frederick R Appelbaum; Veronika Bachanova; Juliet N Barker; Claudio G Brunstein; John Gibson; Partow Kebriaei; Hillard M Lazarus; Richard Olsson; Miguel-Angel Perales; Joseph Pidala; Bipin Savani; Vanderson Rocha; Mary Eapen
Journal:  Haematologica       Date:  2013-09-20       Impact factor: 9.941

5.  Similar overall survival using sibling, unrelated donor, and cord blood grafts after reduced-intensity conditioning for older patients with acute myelogenous leukemia.

Authors:  Régis Peffault de Latour; Claudio G Brunstein; Raphael Porcher; Patrice Chevallier; Marie Robin; Erica Warlick; Alienor Xhaard; Celalettin Ustun; Jérôme Larghero; Nathalie Dhedin; Mohamad Mohty; Gerard Socié; Daniel Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2013-06-18       Impact factor: 5.742

6.  Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis.

Authors:  Mary Eapen; Vanderson Rocha; Guillermo Sanz; Andromachi Scaradavou; Mei-Jie Zhang; William Arcese; Anne Sirvent; Richard E Champlin; Nelson Chao; Adrian P Gee; Luis Isola; Mary J Laughlin; David I Marks; Samir Nabhan; Annalisa Ruggeri; Robert Soiffer; Mary M Horowitz; Eliane Gluckman; John E Wagner
Journal:  Lancet Oncol       Date:  2010-07       Impact factor: 41.316

7.  Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study.

Authors:  Mary Eapen; Pablo Rubinstein; Mei-Jie Zhang; Cladd Stevens; Joanne Kurtzberg; Andromachi Scaradavou; Fausto R Loberiza; Richard E Champlin; John P Klein; Mary M Horowitz; John E Wagner
Journal:  Lancet       Date:  2007-06-09       Impact factor: 79.321

8.  Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research.

Authors:  Sergio Giralt; Karen Ballen; Douglas Rizzo; Andreas Bacigalupo; Mary Horowitz; Marcelo Pasquini; Brenda Sandmaier
Journal:  Biol Blood Marrow Transplant       Date:  2009-03       Impact factor: 5.742

Review 9.  The role of the thymus in T-cell immune reconstitution after umbilical cord blood transplantation.

Authors:  Ioannis Politikos; Vassiliki A Boussiotis
Journal:  Blood       Date:  2014-10-06       Impact factor: 22.113

10.  Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis.

Authors:  Julia A Brown; Kristen Stevenson; Haesook T Kim; Corey Cutler; Karen Ballen; Sean McDonough; Carol Reynolds; Maria Herrera; Deborah Liney; Vincent Ho; Grace Kao; Philippe Armand; John Koreth; Edwin Alyea; Steve McAfee; Eyal Attar; Bimalangshu Dey; Thomas Spitzer; Robert Soiffer; Jerome Ritz; Joseph H Antin; Vassiliki A Boussiotis
Journal:  Blood       Date:  2010-01-27       Impact factor: 22.113

View more
  24 in total

1.  Optimal Donor for African Americans with Hematologic Malignancy: HLA-Haploidentical Relative or Umbilical Cord Blood Transplant.

Authors:  Scott R Solomon; Andrew St Martin; Mei-Jie Zhang; Karen Ballen; Asad Bashey; Minoo Battiwalla; Lee Ann Baxter-Lowe; Claudio Brunstein; Saurabh Chhabra; Miguel Angel Diaz Perez; Ephraim J Fuchs; Siddhartha Ganguly; Nancy Hardy; Peiman Hematti; Joseph McGuirk; Edward Peres; Olle Ringden; David Rizzieri; Rizwan Romee; Melhem Solh; David Szwajcer; Marjolein van der Poel; Edmund Waller; Basem M William; Mary Eapen
Journal:  Biol Blood Marrow Transplant       Date:  2020-07-07       Impact factor: 5.742

2.  Double unrelated umbilical cord blood versus HLA-haploidentical bone marrow transplantation (BMT CTN 1101).

Authors:  Ephraim J Fuchs; Paul V O'Donnell; Mary Eapen; Brent R Logan; Joseph H Antin; Peter Dawson; Steven M Devine; Mary M Horowitz; Mitchell E Horwitz; Chatchada Karanes; Eric Leifer; John M Magenau; Joseph Patrick McGuirk; Lawrence E Morris; Andrew R Rezvani; Richard J Jones; Claudio G Brunstein
Journal:  Blood       Date:  2020-08-31       Impact factor: 22.113

3.  Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1.

Authors:  Celalettin Ustun; Soyoung Kim; Min Chen; Amer M Beitinjaneh; Valerie I Brown; Parastoo B Dahi; Andrew Daly; Miguel Angel Diaz; Cesar O Freytes; Siddhartha Ganguly; Shahrukh Hashmi; Gerhard C Hildebrandt; Hillard M Lazarus; Taiga Nishihori; Richard F Olsson; Kristin M Page; Genovefa Papanicolaou; Ayman Saad; Sachiko Seo; Basem M William; John R Wingard; Baldeep Wirk; Jean A Yared; Miguel-Angel Perales; Jeffery J Auletta; Krishna V Komanduri; Caroline A Lindemans; Marcie L Riches
Journal:  Blood Adv       Date:  2019-09-10

4.  Robust CD4+ T-cell recovery in adults transplanted with cord blood and no antithymocyte globulin.

Authors:  Ioannis Politikos; Jessica A Lavery; Patrick Hilden; Christina Cho; Taylor Borrill; Molly A Maloy; Sergio A Giralt; Marcel R M van den Brink; Miguel-Angel Perales; Juliet N Barker
Journal:  Blood Adv       Date:  2020-01-14

Review 5.  Engineering cord blood to improve engraftment after cord blood transplant.

Authors:  Rohtesh S Mehta; Hema Dave; Catherine M Bollard; Elizabeth J Shpall
Journal:  Stem Cell Investig       Date:  2017-05-25

Review 6.  Clostridioides difficile Infection in the Stem Cell Transplant and Hematologic Malignancy Population.

Authors:  Elizabeth Ann Misch; Nasia Safdar
Journal:  Infect Dis Clin North Am       Date:  2019-06       Impact factor: 5.982

7.  Adult Umbilical Cord Blood Transplantation Using Myeloablative Thiotepa, Total Body Irradiation, and Fludarabine Conditioning.

Authors:  Sarah Anand; Samantha Thomas; Kelly Corbet; Cristina Gasparetto; Gwynn D Long; Richard Lopez; Ashley K Morris; David A Rizzieri; Keith M Sullivan; Anthony D Sung; Stefanie Sarantopoulos; Nelson J Chao; Mitchell E Horwitz
Journal:  Biol Blood Marrow Transplant       Date:  2017-07-17       Impact factor: 5.742

8.  A Modified Intensive Strategy to Prevent Cytomegalovirus Disease in Seropositive Umbilical Cord Blood Transplantation Recipients.

Authors:  Joshua Aiden Hill; Steven A Pergam; Emily Cox; Hu Xie; Wendy M Leisenring; Michael Boeckh; Colleen Delaney; Filippo Milano
Journal:  Biol Blood Marrow Transplant       Date:  2018-05-16       Impact factor: 5.742

Review 9.  Foiling fungal disease post hematopoietic cell transplant: review of prophylactic strategies.

Authors:  S M Rubinstein; K A Culos; B Savani; G Satyanarayana
Journal:  Bone Marrow Transplant       Date:  2017-10-23       Impact factor: 5.483

10.  Unlicensed Umbilical Cord Blood Units Provide a Safe and Effective Graft Source for a Diverse Population: A Study of 2456 Umbilical Cord Blood Recipients.

Authors:  Karen Ballen; Brent R Logan; Pintip Chitphakdithai; Michelle Kuxhausen; Stephen R Spellman; Alexia Adams; Rebecca J Drexler; Merry Duffy; Ann Kemp; Roberta King; Aleksandar Babic; Colleen Delaney; Chatchada Karanes; Joanne Kurtzberg; Lawrence Petz; Andromachi Scaradavou; Elizabeth J Shpall; Clayton Smith; Dennis L Confer; John P Miller
Journal:  Biol Blood Marrow Transplant       Date:  2019-11-19       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.